World

Nivolumab/Ipilimumab Improves Real-World Melanoma Outcomes Vs Pembrolizumab

Russ Conroy
Russ Conroy
0 Min Read
At 1 and 2 years, the progression-free survival rates were higher with nivolumab plus ipilimumab vs pembrolizumab in patients with cutaneous melanoma.

This post was originally published on this site

Previous Article Roosevelt’s Sports Mentoring & Youth Scouting announces October VELT Award recipients
Next Article JFK’s grandson Jack Schlossberg enters Congress race, vows to amplify voices of NY
Healthy in the home office health reviews. balanced health vibes health & fitness. australia brisbane sydney adelaide melbourne perth hobart darwin canberra nsw qld nt sa wa tas.